Zymeworks is gaining momentum as Ziihera shows strong Phase III data in HER2+ gastroesophageal adenocarcinoma, supporting growth and de-risking the investment. ZYME's royalty-based business model with ...
– Study data suggests IGV-001 provides patients with a clinically meaningful improvement in overall survival (+6.3 months; +45%) compared to the current standard of care for ndGBM – – Company plans to ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results